GlassScriptPhysician profile
Joseph T Pham
NPI 1891727814
$9,784.98
in general payments reported to CMS, 2019-2025
24 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,480 · 2020: $409 · 2021: $1,240 · 2022: $1,165 · 2023: $1,637 · 2024: $1,441 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,491.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $3,428.28 | 2020-2025 | Idosetr, Istent Infinite, Idose |
| Allergan, INC. | $2,510.77 | 2019-2022 | |
| Abbvie INC. | $986.16 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $706.71 | 2019-2025 | Tecnis Iol, Catalys System, Tecnis Simplicity |
| Alcon Vision LLC | $435.35 | 2019-2025 | Rocklatan, Clareon, Acrysof, Iq Restor |
| Rxsight INC | $210.87 | 2022-2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Sun Pharmaceutical Industries INC. | $201.00 | 2019-2025 | |
| Astellas Pharma US INC | $156.93 | 2024 | Izervay |
| Rayner Intraocular Lenses Limited | $150.58 | 2022-2025 | Rayone Spheric, Rayner Cataract Set 1, Rayone Emv |
| New World Medical,INC. | $134.31 | 2019-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Via360 |
| Genentech USA, INC. | $109.87 | 2023 | Vabysmo |
| Aerie Pharmaceuticals, INC. | $104.42 | 2019-2021 | |
| Thea Pharma INC. | $103.64 | 2022-2025 | Iyuzeh |
| Biotissue Holdings INC. | $98.08 | 2022-2023 | |
| Oyster Point Pharma, INC. | $78.08 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $64.80 | 2024-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $58.85 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $56.24 | 2022-2025 | Vyzulta |
| Kala Pharmaceuticals, INC. | $50.99 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $47.09 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $36.91 | 2019 | |
| Sight Sciences, INC. | $21.25 | 2022 | |
| Mallinckrodt Enterprises LLC | $20.16 | 2019 | |
| Iridex Corporation | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.